Trial intelligence / Profile preview

Veliparib combinations versus placebo plus carboplatin/paclitaxel in BRCA-mutated metastatic breast cancer

2011-002913-12Phase 2Completed

Sponsor
AbbVie Inc.
Start
Dec 2011
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of veliparib in breast cancer (3 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Started Dec 2011; status: completed.

02

Drugs

veliparib
03

Conditions

breast cancer

Beyond the preview

Go deeper on 2011-002913-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-002913-12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call